SMAD3 and neoplasm: Third, considering the effect of SMAD3 on the tumor aggressiveness phenotype, regardless the impact on chemoradiotherapy (Liu et al., 2015; Romano et al., 2016; Tauriello and Batlle, 2016), a non-treated control group would have been helpful to clarify the contribution of SMAD3 on tumor response to treatment.